SCHEMBL24315934

SCHEMBL24315934

O=C1Nc2ccnc3c(N4CCN(Cc5ccccc5)CC4)ccc1c23

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.49
DRD4 P21917 6/20 0.49
DRD3 P35462 6/20 0.49
ALDH1A1 P00352 1/20 0.46
TRPC5 Q9UL62 1/20 0.45
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CASP1 P29466 1/20 0.43
CASP5 P51878 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALK Q9UM73 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315968 0.81 PARP1 (0.43) DRD2DRD4DRD3
SCHEMBL24315958 0.80 SIGMAR1 (0.40) DRD2ALDH1A1NPSR1HTR2CHRH3
SCHEMBL24316091 0.79 HRH3 (0.38) DRD2DRD4DRD3HRH3
SCHEMBL24315760 0.74 CRBN (0.51) DRD2ALDH1A1TDP1
SCHEMBL26664920 0.69 CA12 (0.39) DRD2DRD4DRD3ALDH1A1TRPC5
SCHEMBL6637562 0.69 DRD2 (0.61) DRD2DRD4DRD3ALDH1A1HTR3E
SCHEMBL4202385 0.69 MAPT (0.63) DRD2DRD4DRD3ALDH1A1TRPC5
SCHEMBL8311608 0.68 MAPT (0.62) DRD2DRD4DRD3ALDH1A1TRPC5
SCHEMBL5364887 0.67 DRD2 (0.55) DRD2DRD4DRD3ALDH1A1MAPT
SCHEMBL7986532 0.67 TSHR (0.46) DRD2DRD4DRD3ALDH1A1TRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 DRD2 4565/4885DRD4 4322/4885DRD3 4418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.